在患有高危早期三阴性或激素受体受体正/HER-2阴性乳腺癌(MK-1022-010,Herthena-Breast-03)的参与者中,Patritumab Deruxtecan加Pembrolizumab与其他抗癌药物的研究
一项开放标签的2阶段2研究,用于评估patritumab deruxtecan和pembrolizumab的安全性和功效阴性或激素受体 - 低阳性/人表皮生长因子受体-2阴性乳腺癌(Herthena-breast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Toll Free Number
- 电话号码:1-888-577-8839
- 邮箱:Trialsites@msd.com
学习地点
-
-
-
Taichung、台湾、407
- 招聘中
- Taichung Veterans General Hospital ( Site 2502)
-
接触:
- Study Coordinator
- 电话号码:+886423592525
-
Tainan、台湾、704
- 招聘中
- National Cheng Kung University Hospital ( Site 2503)
-
接触:
- Study Coordinator
- 电话号码:+88662353535
-
Taipei、台湾、112
- 招聘中
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
接触:
- Study Coordinator
- 电话号码:886228970011x1686
-
-
-
-
California
-
Santa Monica、California、美国、90404
- 招聘中
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
接触:
- Study Coordinator
- 电话号码:424-402-9520
-
-
Illinois
-
Skokie、Illinois、美国、60077
- 招聘中
- Orchard Healthcare Research Inc. ( Site 0006)
-
接触:
- Study Coordinator
- 电话号码:847-568-9932
-
-
Montana
-
Billings、Montana、美国、59102
- 招聘中
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
接触:
- Study Coordinator
- 电话号码:406-238-6685
-
-
Oregon
-
Happy Valley、Oregon、美国、97015
- 招聘中
- Northwest Cancer Specialists, P.C. ( Site 8003)
-
接触:
- Study Coordinator
- 电话号码:360-944-9889
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- SCRI Oncology Partners ( Site 7000)
-
接触:
- Study Coordinator
- 电话号码:844-482-4812
-
-
Texas
-
Dallas、Texas、美国、75246
- 招聘中
- Texas Oncology - DFW ( Site 8000)
-
接触:
- Study Coordinator
- 电话号码:214-370-1067
-
Houston、Texas、美国、77030
- 招聘中
- Houston Methodist Hospital ( Site 0022)
-
接触:
- Study Coordinator
- 电话号码:713-441-9948
-
-
Virginia
-
Norfolk、Virginia、美国、23502
- 招聘中
- Virginia Oncology Associates (VOA) ( Site 8001)
-
接触:
- Study Coordinator
- 电话号码:844-482-4812
-
-
-
-
-
Córdoba、西班牙、14004
- 招聘中
- Hospital Universitario Reina Sofia ( Site 1702)
-
接触:
- Study Coordinator
- 电话号码:+34 957012408
-
-
Catalonia
-
Badalona、Catalonia、西班牙、08916
- 招聘中
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
接触:
- Study Coordinator
- 电话号码:+34934978925
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、西班牙、28027
- 招聘中
- Clinica Universidad de Navarra ( Site 1703)
-
接触:
- Study Coordinator
- 电话号码:+34913531920
-
-
-
-
-
Seoul、韩国、03080
- 招聘中
- Seoul National University Hospital ( Site 2400)
-
接触:
- Study Coordinator
- 电话号码:+82220720850
-
Seoul、韩国、05505
- 招聘中
- Asan Medical Center ( Site 2401)
-
接触:
- Study Coordinator
- 电话号码:+82230103217
-
Seoul、韩国、03722
- 招聘中
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
接触:
- Study Coordinator
- 电话号码:+82222288135
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. |
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
|
|
实验性的:Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
其他名称:
|
|
实验性的:Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
其他名称:
|
|
有源比较器:Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles. |
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
其他名称:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
大体时间:Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1. |
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
大体时间:Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity. |
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
大体时间:Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1. |
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
大体时间:Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
大体时间:Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2. |
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
大体时间:Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2. |
Up to ~90 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
大体时间:Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
大体时间:Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
大体时间:Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
大体时间:Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
大体时间:Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28). |
Up to ~30 weeks
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 按部位分类的肿瘤
- 肿瘤
- 皮肤病
- 乳腺疾病
- 皮肤和结缔组织疾病
- 乳腺肿瘤
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 核酸,核苷酸和核苷
- 碳氢化合物
- 环磷脂
- 碳氢化合物,Alicyclic
- 碳氢化合物,循环
- 萜烯
- 碳水化合物
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 协调配合物
- 税类
- 环虫
- 二萜
- 脱氧胞苷
- 胞苷
- 嘧啶核苷
- 嘧啶
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 核苷
- 乌拉西尔
- 嘧啶酮
- 蒽环类动物
- 萘烯
- 氨基糖苷
- Daunorubicin
- 脱氧核糖核苷
- 氟尿嘧啶
- 卡培他滨
- 环磷酰胺
- 卡铂
- 阿霉素
- 紫杉醇
- 表阿霉素
- Pembrolizumab
- 奥拉帕里布
- patritumab deruxtecan
其他研究编号
- 1022-010
- MK-1022-010 (其他标识符:MSD)
- U1111-1307-7867 (注册表标识符:UTN)
- 2024-514376-40-00 (注册表标识符:EU CT)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.